Sean Juo

President And Chief Scientific Officer at HanchorBio Inc. 漢康生技股份有限公司

Sean Juo has a diverse and extensive work experience spanning several industries and positions. Currently, they are the President and Chief Scientific Officer of HanchorBio Inc, where they oversee the company's operations and engages in business development. Prior to this, they served as the Director of Protein Engineering & Immune Cytokines at Dragonfly Therapeutics, Inc. and as a Principal Scientist at Pfizer, where they focused on therapeutic antibody discovery and protein engineering. Earlier in their career, they worked as a Research Specialist at Stanford University and as an Associate Research Scientist at Yale University, where they conducted research and published several scientific papers. Additionally, Sean has served in the ROC (Taiwan) Army Ordnance Corps.

Sean Juo has a Bachelor of Science degree in Chemical Engineering from National Central University, which they completed from 1983 to 1987. Sean then pursued their education at UCLA, where they were a Candidate in Philosophy in Biochemistry and Structural Biology from 1990 to 1992. After that, they earned their Doctor of Philosophy (PhD) degree in Biochemistry and Structural Biology from UCLA between 1992 and 1996. Sean later continued their studies at the Yale University School of Medicine from 1996 to 1999, where they worked as a Postdoctoral Associate for the Howard Hughes Medical Institute, specializing in Molecular Biophysics and Biochemistry.

Location

Taipei, Taiwan, Province of China

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


HanchorBio Inc. 漢康生技股份有限公司

HanchorBio (漢康生技) is developing a technology for the creation of next generation personalized biotherapeutics. Based in San Francisco, Taipei, and Shanghai, we are led by a group of pharmaceutical industry veterans with proven track-record of success is biologics discovery and global development with bold vision to rewrite immunotherapies. Committed to reactivating the immune system to fight against diseases, our proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to help revolutionize the treatment of people with cancer and other debilitating diseases. Our FBDB™ platform has successfully delivered proof-of-concept data in several in-vivo animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing methodology in CMC, we develop transformative medicines to address unmet medical needs.